Patents Represented by Attorney Arnall Golden Gregory
-
Patent number: 6002961Abstract: Applications of low-frequency (20 KHz) ultrasound enhances transdermal transport of high-molecular weight proteins. This method includes a simultaneous application of ultrasound and protein on the skin surface in order to deliver therapeutic doses of proteins across the skin. Examples demonstrate in vitro and in vivo administration of insulin (molecular weight 6,000 D), and in vitro administration of gamma interferon (molecular weight 17,000 D), and erythropoeitin (molecular weight 48,000 D).Type: GrantFiled: July 25, 1995Date of Patent: December 14, 1999Assignee: Massachusetts Institute of TechnologyInventors: Samir S. Mitragotri, Daniel Blankschtein, Robert S. Langer
-
Patent number: 5997863Abstract: Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors.Type: GrantFiled: July 8, 1994Date of Patent: December 7, 1999Assignee: Ibex Technologies R and D, Inc.Inventors: Joseph Zimmermann, Israel Vlodavsky, Clark Bennett, Pamela Danagher, Richard Broughton
-
Patent number: 5998588Abstract: The combination of the capabilities of stimuli-responsive components such as polymers and interactive molecules to form site-specific conjugates which are useful in a variety of assays, separations, processing, and other uses is disclosed. The polymer chain conformation and volume can be manipulated through alteration in pH, temperature, light, or other stimuli. The interactive molecules can be biomolecules like proteins or peptides, such as antibodies, receptors, or enzymes, polysaccharides or glycoproteins which specifically bind to ligands, or nucleic acids such as antisense, ribozymes, and aptamers, or ligands for organic or inorganic molecules in the environment or manufacturing processes.Type: GrantFiled: August 30, 1996Date of Patent: December 7, 1999Assignee: University of WashingtonInventors: Allan S. Hoffman, Patrick S. Stayton
-
Patent number: 5994079Abstract: Disclosed is a method of detecting RNA molecules of interest in which reverse transcription primers unique to the RNA molecule of interest are used for reverse transcribing the RNA with a reverse transcriptase lacking RNAse H function and the resulting RNA/DNA hybrid is detected with an antibody specific for RNA/DNA hybrids. This method can be used to detect the presence of one or many specific RNA molecules which may be present in a sample, including RNA from different organisms (such as viruses, bacteria, fungi, plants, and animals), or RNA indicative of an infection, a disease state, or predisposition to a disease in an animal. The specificity of detection is increased relative to current detection methods involving probe hybridization since the reverse transcription primers are shorter and less subject to non-specific hybridization. Specificity of the disclosed method can also be increased by using a thermostable reverse transcriptase and performing reverse transcription at a high temperature.Type: GrantFiled: February 6, 1998Date of Patent: November 30, 1999Assignee: Digene CorporationInventors: Abel De La Rosa, Clayton D. Collier
-
Patent number: 5993856Abstract: Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.Type: GrantFiled: November 17, 1997Date of Patent: November 30, 1999Assignee: FemmePharmaInventors: Vanaja V. Ragavan, Gerrianne M. DiPiano
-
Patent number: 5990081Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: August 5, 1998Date of Patent: November 23, 1999Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Romander
-
Patent number: 5989898Abstract: Methods for packaging Metarhizium fungal cultures or conidia are described. In one embodiment, the fungal culture is provided within an insect infection chamber that attracts insects, then infects them with a lethal dosage of fungus, where the packaging maintains high humidity within the chamber, allows free exchange of gases, and is impermeable to microbes, including fungal spores, viruses, and bacteria. In a second embodiment, the fungal conidia are packaged under conditions which maintain high viability even after long-term storage at both 25.degree. C. and 37.degree. C., i.e., low relative humidity and oxygen. The conidia can then be reactivated for the use in the control of insects such as cockroaches, flies, ants, soft-bodied insects, turf pests, and caterpillars.Type: GrantFiled: May 27, 1993Date of Patent: November 23, 1999Assignee: EcoScience CorporationInventors: Xixuan Jin, Kathryn E. Grigas, Carol Ann Johnson, Paul Perry, David W. Miller
-
Patent number: 5989925Abstract: A monoclonal antibody, Serex A93, recognizes peptide linked pyridinoline in Type I bone collagen fragments and can be used to quantitate bone resorption. The hybridoma producing this antibody has been deposited with the American Type Culture Collection, Rockville, Md., under accession number HB-12254. The epitope reactive with the antibody is stable to acid hydrolysis and therefore is not a linear peptide. The antibody recognizes pyridinoline in bound or conjugated form, but not in the free form found in urine. The antibody is useful in immunoassays for determining bone resorption, utilizing body fluids such as urine, saliva, blood, or sweat.Type: GrantFiled: June 27, 1997Date of Patent: November 23, 1999Assignee: Serex, Inc.Inventors: Judith Fitzpatrick, Regina Lenda, Zijian Zeng
-
Patent number: 5985312Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery devices. The bioadhesive properties of a polymer are enhanced by incorporating a metal compound into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Metal compounds which enhance the bioadhesive properties of a polymer include water-insoluble metal compounds such as water-insoluble metal oxides, including oxides of calcium, iron, copper and zinc. The metal compounds can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, metal oxides can be incorporated within polymers used to form or coat drug delivery devices, such as microspheres, which contain a drug or diagnostic agent.Type: GrantFiled: January 26, 1996Date of Patent: November 16, 1999Assignee: Brown University Research FoundationInventors: Jules S. Jacob, Edith Mathiowitz
-
Patent number: 5983835Abstract: Animals are trained to stand and stay with all four feet on the ground in the desired position by placing the animal's feet on four stable, elevated, immobilized supports, then praising the animal for standing in the desired position. This process is repeated until the animal has learned the meaning of the command to stand and stay. It is essential that the supports be immobilizable and sturdy enough to support the animal without the animal being afraid it will fall. In the preferred embodiment, the upper surface of the supports are approximately the same size as, or only slightly larger than, the animal's foot, and is covered with a non-slip surface. The support is designed to elevate the animal's foot so that it does not want to remove the foot to the surface on which the support is immobilized. The supports must be immobilizable relative to each other so that the animal is forced to stand in the desired position.Type: GrantFiled: September 19, 1997Date of Patent: November 16, 1999Inventor: Susan Carlyle Catlin
-
Patent number: 5986043Abstract: Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces.Type: GrantFiled: August 20, 1996Date of Patent: November 16, 1999Assignee: Board of Regents, The University of Texas SystemInventors: Jeffrey A. Hubbell, Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Neil P. Desai, Jennifer L. Hill-West
-
Patent number: 5985354Abstract: Two or more hydrophilic polymers that are not soluble in each other at a particular concentration and temperature, but which have a positive spreading coefficient in solution, are used to form multi-layered polymeric microspheres. The multi-layer microspheres produced by the method are distinguished by extremely uniform dimensioned polymer layers and actual incorporation of a substance to be delivered into the polymer layers. In the preferred embodiment of the method, two polymers are dissolved in an aqueous solvent, the substance to be incorporated is dispersed or dissolved in the polymer solution, the mixture is suspended in an organic solvent or polymer/water mixture and stirred, and the solvent is slowly evaporated, creating microspheres with an inner core formed by one polymer and an outer layer formed by the second polymer.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignee: Brown University Research FoundationInventors: Edith Mathiowitz, Jules S. Jacob, Donald E. Chickering, III, Kathleen Jo Pekarek
-
Patent number: 5977321Abstract: Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.Type: GrantFiled: August 8, 1991Date of Patent: November 2, 1999Assignee: Massachusetts Institute of TechnologyInventors: Haruo Saito, David M. Kranz, Herman N. Eisen, Susumu Tonegawa
-
Patent number: 5976874Abstract: External guide sequences ("EGS") can be used to promote RNAase P-mediated cleavage of RNA transcribed from plasmids and other genetic elements which confer drug resistance on bacterial cells. Such cleavage can render the bacteria drug sensitive. In a preferred embodiment, a vector encoding an EGS is administered to an animal or human harboring antibiotic resistant bacterial cells such that the EGS is expressed in the bacterial cells, the EGS promotes RNAase P-mediated cleavage of RNA involved in conferring antibiotic resistance to the cells, and the cells are rendered antibiotic sensitive. A preferred form of administration is via inoculation of the animal or human with cells containing genes for appropriate EGSs on promiscuous plasmids. These plasmids will spread quickly through the antibiotic-resistant population of bacterial cells, thereby making the cells susceptible to antibiotic therapy.Type: GrantFiled: August 15, 1997Date of Patent: November 2, 1999Assignee: Yale UniversityInventors: Sidney Altman, Cecilia Guerrier-Takada
-
Patent number: 5962426Abstract: A high affinity, triplex-forming oligonucleotide and methods for use thereof wherein an oligonucleotide is used to form a triple-stranded nucleic acid molecule with a specific DNA segment of a target DNA molecule. Upon formation of the triplex, the binding of the oligonucleotide stimulates mutagenesis within or adjacent to the target sequence using cellular DNA synthesis or repair mechanisms. The mutation activates, inactivates or alters the activity and function of the target molecule.Type: GrantFiled: June 7, 1995Date of Patent: October 5, 1999Assignee: Yale UniversityInventor: Peter M. Glazer
-
Patent number: 5962322Abstract: Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels.Type: GrantFiled: November 15, 1996Date of Patent: October 5, 1999Assignees: Massachusetts Institute of Technology, The Trustees of the University of PennsylvaniaInventors: Karen Kozarsky, Attilio Rigotti, Monty Krieger
-
Patent number: 5962532Abstract: Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof is to be administered, and then administering an effective concentration of capsaicin to the joint. The anesthesia can be provided directly to the site, or at remote site that causes anesthesia at the site where the capsaicin is to be administered. For example, epidural regional anesthesia can be provided to patients to which the capsaicin is to be administered at a site located from the waist down. By pretreating the site with the anesthetic, a significantly higher concentration of capsaicin can be used. Effective concentrations of capsaicin or analogues thereof range from between 0.01 and 10% by weight, preferably between 1 and 7.5% by weight, and more preferably, about 5% by weight.Type: GrantFiled: March 12, 1998Date of Patent: October 5, 1999Inventors: James N. Campbell, Marco Pappagallo, Richard A. Meyer
-
Patent number: 5955096Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery systems. The bioadhesive properties of a polymer are enhanced by incorporating an anhydride oligomer into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydride oligomers which enhance the bioadhesive properties of a polymer include oligomers synthesized from dicarboxylic acid monomers, preferably those found in Krebs glycolysis cycle, especially fumaric acid. The oligomers can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, anhydride oligomers can be incorporated within polymers used to form or coat drug delivery systems, such as microspheres, which contain a drug or diagnostic agent. The oligomers can either be solubilized and blended with the polymer before manufacture or else used as a coating with polymers over existing systems.Type: GrantFiled: June 25, 1996Date of Patent: September 21, 1999Assignee: Brown University Research FoundationInventors: Camila A. Santos, Jules S. Jacob, Benjamin A. Hertzog, Gerardo P. Carino, Edith Mathiowitz
-
Patent number: 5955441Abstract: A method and means for protecting cells and transplanted organs from the effects of activated complement proteins generated in blood serum or plasma by introducing the gene for CD59 into the cells to be protected is described. In an example of the method, protection against the pore-forming activity of the human C5b-9 proteins was conferred on CHO cells by transfection with cDNA encoding the human complement regulatory protein CD59.Type: GrantFiled: August 13, 1996Date of Patent: September 21, 1999Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L.M. Bothwell
-
Patent number: 5947921Abstract: Transdermal transport of molecules during sonophoresis (delivery or extraction) can be further enhanced by providing chemical enhancers which increase the solubility of the compound to be transported and/or lipid bilayer solubility, and/or additional driving forces for transport, such as mechanical or osmotic pressure, magnetic fields, electroporation or iontophoresis. In a preferred embodiment the ultrasound is low frequency ultrasound which induces cavitation of the lipid layers of the stratum corneum (SC). This method provides higher drug transdermal fluxes, allows rapid control of transdermal fluxes, and allows drug delivery or analyte extraction at lower ultrasound intensities and other forces or concentrations than that required if each means of enhancing transport is used individually.Type: GrantFiled: December 18, 1995Date of Patent: September 7, 1999Assignee: Massachusetts Institute of TechnologyInventors: Mark E. Johnson, Samir S. Mitragotri, Daniel Blankschtein, Robert S. Langer, Michael Pishko, Joseph Kost